Personalis EBIT Margin 2018-2023 | PSNL
Current and historical EBIT (Earnings Before Interest & Taxes) margin for Personalis (PSNL) over the last 10 years. The current EBIT profit margin for Personalis as of December 31, 2023 is .
| Personalis EBIT Margin Historical Data |
| Date |
TTM Revenue |
TTM EBIT |
EBIT Margin |
| 2023-12-31 |
$0.07B |
$-0.11B |
-148.65% |
| 2023-09-30 |
$0.07B |
$-0.12B |
-166.20% |
| 2023-06-30 |
$0.07B |
$-0.11B |
-167.65% |
| 2023-03-31 |
$0.07B |
$-0.12B |
-169.57% |
| 2022-12-31 |
$0.07B |
$-0.12B |
-176.92% |
| 2022-09-30 |
$0.07B |
$-0.10B |
-149.28% |
| 2022-06-30 |
$0.08B |
$-0.09B |
-123.68% |
| 2022-03-31 |
$0.08B |
$-0.08B |
-101.25% |
| 2021-12-31 |
$0.09B |
$-0.07B |
-75.58% |
| 2021-09-30 |
$0.09B |
$-0.06B |
-68.24% |
| 2021-06-30 |
$0.08B |
$-0.05B |
-60.24% |
| 2021-03-31 |
$0.08B |
$-0.04B |
-55.00% |
| 2020-12-31 |
$0.08B |
$-0.04B |
-53.85% |
| 2020-09-30 |
$0.08B |
$-0.04B |
-47.37% |
| 2020-06-30 |
$0.07B |
$-0.03B |
-43.84% |
| 2020-03-31 |
$0.07B |
$-0.03B |
-38.57% |
| 2019-12-31 |
$0.07B |
$-0.02B |
-33.85% |
| 2019-06-30 |
$0.04B |
$-0.01B |
-26.19% |
| 2019-03-31 |
$0.04B |
$-0.01B |
-31.43% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.074B |
$0.073B |
|
Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California.
|
